Multivariate Cox model of event-free, relapse-free, and overall survival for children treated on MRC ALL97
| Variable . | Hazard ratio . | P . | 95% CI . |
|---|---|---|---|
| Event-free survival | |||
| ALL99 vs ALL97 | 0.70 | .012 | 0.53-0.93 |
| Dexamethasone vs prednisolone | 0.68 | .010 | 0.51-0.91 |
| Age | 1.05 | .005 | 1.02-1.09 |
| Sex (male vs female) | 1.06 | .700 | 0.80-1.38 |
| White cell count | 1.19 | .001 | 1.08-1.33 |
| Good vs intermediate cytogenetic risk group* | 0.63 | .009 | 0.44-0.89 |
| Poor vs intermediate cytogenetic risk group* | 2.35 | < .001 | 1.62-3.40 |
| Down syndrome (yes vs no) | 3.64 | < .001 | 1.96-6.77 |
| CRLF2 deregulation (yes vs no) | 1.45 | .140 | 0.88-2.39 |
| Relapse-free survival | |||
| ALL99 vs ALL97 | 0.68 | .012 | 0.50-0.92 |
| Dexamethasone vs prednisolone | 0.55 | < .001 | 0.40-0.77 |
| Age | 1.06 | .003 | 1.02-1.10 |
| Sex (male vs female) | 1.01 | .962 | 0.75-1.36 |
| White cell count | 1.15 | .020 | 1.02-1.29 |
| Good vs intermediate cytogenetic risk group* | 0.64 | .024 | 0.44-0.94 |
| Poor vs intermediate cytogenetic risk group* | 2.24 | < .001 | 1.49-3.38 |
| Down syndrome (yes vs no) | 1.24 | .686 | 0.44-3.50 |
| CRLF2 deregulation (yes vs no) | 1.67 | .070 | 0.96-2.91 |
| Overall survival | |||
| ALL99 vs ALL97 | 0.63 | .013 | 0.44-0.91 |
| Dexamethasone vs prednisolone | 0.88 | .503 | 0.61-1.28 |
| Age | 1.07 | .001 | 1.03-1.12 |
| Sex (male vs female) | 0.99 | .966 | 0.70-1.41 |
| White cell count | 1.30 | < .001 | 1.14-1.48 |
| Good vs intermediate cytogenetic risk group† | 0.52 | .008 | 0.32-0.84 |
| Poor vs intermediate cytogenetic risk group† | 2.73 | < .001 | 1.74-4.30 |
| Down syndrome (yes vs no) | 5.43 | < .001 | 2.74-10.77 |
| CRLF2 deregulation (yes vs no) | 1.90 | .027 | 1.08-3.36 |
| Variable . | Hazard ratio . | P . | 95% CI . |
|---|---|---|---|
| Event-free survival | |||
| ALL99 vs ALL97 | 0.70 | .012 | 0.53-0.93 |
| Dexamethasone vs prednisolone | 0.68 | .010 | 0.51-0.91 |
| Age | 1.05 | .005 | 1.02-1.09 |
| Sex (male vs female) | 1.06 | .700 | 0.80-1.38 |
| White cell count | 1.19 | .001 | 1.08-1.33 |
| Good vs intermediate cytogenetic risk group* | 0.63 | .009 | 0.44-0.89 |
| Poor vs intermediate cytogenetic risk group* | 2.35 | < .001 | 1.62-3.40 |
| Down syndrome (yes vs no) | 3.64 | < .001 | 1.96-6.77 |
| CRLF2 deregulation (yes vs no) | 1.45 | .140 | 0.88-2.39 |
| Relapse-free survival | |||
| ALL99 vs ALL97 | 0.68 | .012 | 0.50-0.92 |
| Dexamethasone vs prednisolone | 0.55 | < .001 | 0.40-0.77 |
| Age | 1.06 | .003 | 1.02-1.10 |
| Sex (male vs female) | 1.01 | .962 | 0.75-1.36 |
| White cell count | 1.15 | .020 | 1.02-1.29 |
| Good vs intermediate cytogenetic risk group* | 0.64 | .024 | 0.44-0.94 |
| Poor vs intermediate cytogenetic risk group* | 2.24 | < .001 | 1.49-3.38 |
| Down syndrome (yes vs no) | 1.24 | .686 | 0.44-3.50 |
| CRLF2 deregulation (yes vs no) | 1.67 | .070 | 0.96-2.91 |
| Overall survival | |||
| ALL99 vs ALL97 | 0.63 | .013 | 0.44-0.91 |
| Dexamethasone vs prednisolone | 0.88 | .503 | 0.61-1.28 |
| Age | 1.07 | .001 | 1.03-1.12 |
| Sex (male vs female) | 0.99 | .966 | 0.70-1.41 |
| White cell count | 1.30 | < .001 | 1.14-1.48 |
| Good vs intermediate cytogenetic risk group† | 0.52 | .008 | 0.32-0.84 |
| Poor vs intermediate cytogenetic risk group† | 2.73 | < .001 | 1.74-4.30 |
| Down syndrome (yes vs no) | 5.43 | < .001 | 2.74-10.77 |
| CRLF2 deregulation (yes vs no) | 1.90 | .027 | 1.08-3.36 |
A total of 821, 808, and 821 cases were included in the event-free, relapse-free, and overall survival models, respectively. Cases were omitted from the model because of missing cytogenetic data (n = 44) or survival information (n = 13).
CI indicates confidence interval; iAMP21, intrachromosomal amplification of chromosome 21; and MRC, Medical Research Council.
Good risk: all patients with high hyperdiploidy or ETV6-RUNX1 except those with t(9;22); poor risk: all patients with t(9;22)/BCR-ABL1, iAMP21, MLL translocations, near haploidy (< 30 chromosomes), low hypodiploidy (30-39 chromosomes), t(17;19)(q23;p13)/TCF3-HLF, abnormal 17p, and loss of 13q (except those with abnormal 17p or loss of 13q and high hyperdiploidy or ETV6-RUNX1); and intermediate risk: all other cases.